Global Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment Market

The nephrology and urology devices market consists of sales of nephrology and urology devices and related services by entities (organizations, sole traders, and partnerships) that produce nephrology and urology devices used in the diagnosis and treatment of kidney and genitourinary diseases. The main types of nephrology and urology devices are dialysis devices and equipment, urinary stone treatment devices and equipment, urinary incontinence and pelvic organ prolapse devices and equipment, benign prostatic hyperplasia (BPH) treatment devices and equipment, and endoscopy devices, and equipment. Dialysis devices and equipment is a machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged, dysfunctional, or missing. The dialysis machine itself is an artificial kidney. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The global nephrology and urology devices market size is expected to grow from $15.85 billion in 2021 to $17.27 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The global nephrology and urology device market size is expected to grow to $23.07 billion in 2026 at a CAGR of 7.5%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the nephrology and urology devices market during the historic period. According to the Population Reference Bureau, the share of the population over the age of 65 in the global population increased to 9% in 2019. The global population aged 65 years or over was 703 million in 2019. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. These factors increased the demand for these products and drove the market during the historic period. The nephrology and urology devices market was limited by the shortage of skilled workforce in most developed and developing countries, during the historic period. Equipment fabrication and integration require specialized skillsets relating to life sciences, pharmaceuticals, electronics, and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled labor was a significant deterrent to the growth of the market during the historic period. The nephrology and urology market is witnessing a rise in new product launches. Due to the high competition in the market, many companies are investing in advanced technologies to widen product portfolios and increase their share in the market. For instance, in March 2020, Medi-Tate an Israel-based medical device company has received authorization for iTind system that is used to implant and remove nitinol devices during bladder neck remodeling. Researchers at Washington University in St. Louis, the University of Illinois at Urbana-Champaign, and Northwestern University together developed a wireless implant to control overactive bladder using LED lights. Major companies in the nephrology and urology devices market include Baxter International Inc, Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B. Braun Group, C. R. and Bard Inc. North America was the largest region in the global nephrology and urology devices market in 2021. Asia Pacific was the second largest region in the global nephrology and urology devices market. The regions covered in the global nephrology and urology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nephrology and urology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The global nephrology and urology devices market is segmented - 1) By Type: Dialysis Devices and Equipment, Urinary Stone Treatment Devices and Equipment, Urinary Incontinence and Pelvic Organ Prolapse Devices and Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment, Endoscopy Devices and Equipment 2) By End-User: Hospitals and Clinics, Diagnostic Laboratories, Others 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The urology medical lasers market consists of sales of urology medical lasers and related services by entities (organizations, sole traders, and partnerships) that manufacture urology medical lasers. Medical lasers are a non-invasive and efficient source of light used for tissue treatment that provides fast healing without discoloration or scarring. Urology medical lasers are used in the treatment of medical conditions related to the urinary system such as urinary stones, benign prostatic hyperplasia (BPH), bladder or prostate cancer, and traumatic injuries. The main types of urology medical lasers are the holmium laser system, diode laser system, thulium laser system, and others. The holmium laser system is the process of removing stones in the bladder, kidneys, ureters, or urethra using lasers. The applications involved are benign prostatic hyperplasia, urolithiasis, non-muscle-invasive bladder cancer, and others. The end-users involved are hospitals, clinics, and others. The global urology medical lasers market size is expected to grow from $0.77 billion in 2021 to $0.82 billion in 2022 at a compound annual growth rate (CAGR) of 6.6%. The global urology medical laser market is expected to grow to $1.04 billion in 2026 at a CAGR of 6.1%. Rising cases of urological disorders contribute to the demand for the urology medical lasers market. Growing urological cases including bladder cancer and prostate diseases among others are boosting the demand for minimally invasive surgeries and related devices. According to the American Institute for Cancer Research’s statistics on bladder statistics, bladder cancer is the sixth most common cancer in men and the 17th most common cancer in women. The surge in urological diseases and conditions increases the demand for urological surgeries and supports the growth of the urology medical lasers market. Major players operating in the market are continuously focusing on developing new products incorporating advanced technology to meet the requirement of medical professionals. For instance, in June 2020, Olympus Corporation, a Japanese manufacturer of innovative medical and surgical products, launched the Soltive SuperPulsed Thulium Fiber Laser System designed for stone lithotripsy and soft tissue applications in urology. The SuperPulsed thulium fiber laser dust stones into very fine particles faster than other laser systems. In April 2019, Olympus Corporation, a Japan-based manufacturer of innovative technology solutions for medical and surgical procedures, acquired Lithotripsy system design and production technology from Cybersonics, Inc. for an undisclosed amount. The acquisition is expected to help Olympus Corporation to expand manufacturing and enhance treatment for stone disease and enable the company to improve clinical outcomes, reduce costs, and enhance the quality of life of patients. Cybersonics, Inc. is a USA-based company engaged in designing and developing medical devices that utilize ultrasonic energy. The medical devices developed by the company include high-power ultrasonic systems used in the field of neurosurgery, urology, and peripheral vascular surgery. Major players in the urology medical lasers market are Olympus Corporation, Ethicon Inc, Stryker Corporation, Boston Scientific Corporation, Richard Wolf GmbH, Cook Medical Incorporated, Karl Storz SE & Co. KG, Lumenis Ltd, Becton Dickinson and Company, and OmniGuide Holdings Inc. North America was the largest region in the urology medical lasers market in 2021. Asia Pacific was the second largest region in the global urology lasers market. The regions covered in the global urology medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the urology medical lasers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global urology medical lasers market is segmented - 1) By Laser Type: Holmium Laser System, Diode Laser System, Thulium Laser System, Others 2) By Application: Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC), Others 3) By End-User: Hospital, Clinic, Others

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others. The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is cancer that develops in the tissue that lines the bladder’s inner surface. There is no involvement of the bladder muscle. The different applications include low-grade tumors, high-grade tumors and distributed through various channels such as hospital pharmacy, retail pharmacy, others. The global bladder cancer drugs market size is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global bladder cancer drug market size is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%. The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market. Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the Center for Drug Research And Development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology. The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration. In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA. Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson. North America is the largest region in the bladder cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the bladder cancer drug market during the forecast period. The regions covered in the bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global bladder cancer drugs market is segmented - 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others

The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy The main types of kidney cancer are renal cell carcinoma (RCC), urothelial carcinoma, others (renal sarcoma, renal lymphoma). Renal cell carcinoma is a disease in which malignant (cancer) cells form in the kidney's tubules. The different products involved are nexavar (sorafenib), sutent (sunitinib), afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), torisel (temsirolimus), proleukin (aldesleukin), others that are used by hospitals, clinics, research center, others. The global kidney cancer drugs market size is expected to grow from $6.85 billion in 2021 to $7.40 billion in 2022 at a compound annual growth rate (CAGR) of 8.0%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global kidney cancer drug market is expected to reach $9.49 billion in 2026 at a CAGR of 6.4%. Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyle of people, consumption of tobacco and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to American Cancer Society Report, around 73,750 new cases of kidney (renal) cancer were diagnosed in the US in 2020. Thus, driving the growth of the kidney cancer drugs market. Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drug, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which specially attacks the spreading points of cancer. Thus, pharmaceutical industry is embracing the targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market. Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis. According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer. The kidney cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for kidney cancer drugs industry in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in kidney cancer drugs industry are required to abide to the regulations under FDA. In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA. Major players in the kidney cancer drugsmarket are Bayer AG, Pfizer Inc, Novartis International AG, Exelixis Inc, F. Hoffmann-La Roche Ag, Genentech Inc., Glaxosmithkline Plc, Active Biotech, Amgen, Thermo Fisher Scientific Inc, Bristol-Myers Squibb, Eisai, Roche, Cipla Limited, Onyx, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Argos Therapeutics, Myriad Genetics Inc, NeoGenomics Laboratories, NanoString Technologies Inc, Sysmex Corporation, Rosetta Genomics, Illumina Inc and Quest Diagnostics Incorporated. North America was the largest region in the kidney cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global kidney cancer drugs market during the forecast period. The regions covered in the global kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global kidney cancer drugs market is segmented - 1) By Type: Renal Cell Carcinoma, Urothelial Carcinoma, Others (Renal Sarcoma, Renal Lymphoma) 2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Others 3) By End-User: Hospitals, Clinics, Research Centers, Others

The diuretic drugs market consists of sales of diuretic drugs and related services. Diuretic drugs help increase the flow of urine by reducing concentration of sodium and chloride in the body. Diuretic drugs include diuril, microzide, indapamide. The main types of diuretic are osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides & thiazide-like diuretics and aldosterone antagonists. An osmotic diuretic is a form of diuretic that prevents water and sodium from being reabsorbed. They are intravenously administered pharmacologically inactive compounds. The different routes of administration include intravenous, oral and is used in hypertension, glaucoma, heart failure, kidney stones. It is distributed through various channels such as hospital pharmacies, independent pharmacies, retail pharmacies, drug stores and online pharmacies. The global diuretics market size is expected to grow from $0.60 billion in 2021 to $0.64 billion in 2022 at a compound annual growth rate (CAGR) of 6.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global diuretic market is expected to reach $0.78 billion in 2026 at a CAGR of 5.0%. The increase in the renal and kidney disorder cases drives the diuretics drug market. In such cases, the kidney does not function properly increase the need for water-pills (diuretic drugs) to maintain a proper flow of urine. The rise in kidney disorders can be attributed to change in lifestyle such as consumption of unhealthy food high in calcium and other minerals. For example, according to the National Kidney Foundation Inc, in 2019, about 1 out of every 7 or 15% of the adult population in America have chronic kidney disease (CKD). The diuretic drugs market is restricted by the stringent regulatory policies governing the market. Several requirements are laid down by the regulatory bodies to manufacture, process and pack the drugs and the companies should abide by various compliances such as FDA's CGMP regulations; Compliance with European Medicines Agency Regulations, WHO Guidelines. For instance, the Current Good Manufacturing Practice (CGMP) regulations of FDA in the USA imposes several regulations under 21 CFR parts 314, 210 and 211, with respect to application and licensing of new and generic drugs, regulations for manufacturing, processing, packaging or holding of drugs, and requirements for finished pharmaceuticals respectively. These regulations negatively impact the growth of the market. A new drug delivery technology called the oral nanoparticle delivery technology is developed to improve the pH and intestinal permeability of the diuretic drugs to increase the digesting capability as majority of these drugs have low water solubility and bioavailability. Drugs such as amlodipine and isradipine having low bioavailability (less number of solvent to get diluted) and high light sensitivity were delivered using Nano emulsion (dispersion that consist of oil, surfactants and aqueous phase) as a drug delivery system. Pharmacokinetics (study of how organism affects drug) data of both the drugs revealed enhanced stability and bioavailability. For instance, Nanomerics, a pharmaceutical nanotechnology drug delivery company is carrying out R&D in this technology by working on MET (Molecule Envelop Technology) Nanoparticles Oral Delivery. Also, in 2020, a Japanese research team from Kumamoto University, developed a new nanocarrier drug delivery technology to enhance the drugs, from moving from the blood into the brain. The manufacturers must comply with the European Medicines Agency’s scientific guidelines on quality that should be maintained in the manufacturing, processing, packaging of the drugs and help manufacturers prepare marketing authorization applications. In addition, the International Council for Harmonization (ICH) guidelines lays down Good Manufacturing Practice (ICHQ7) guide which states that all the utilities like steam, gases, compressed air, heating, ventilation and air condition could impact the quality of the product (drug). Hence, proper monitoring and actions should be executed if limits are exceeded. It has also framed guidelines for Quality Risk Management (ICHQ9) that provides all the risk management methods and tools like FMEA (Failure Mode Effects Analysis), FMECA (Failure Mode, Effects and Criticality Analysis), FTA (Fault Tree Analysis), HACCP (Hazard Analysis and Critically Control Points) and others. In March 2020, AstraZeneca, a UK based pharmaceutical company acquired Atnahs Pharma for $350 million. Through this acquisition AstraZeneca gets the commercial rights to various drugs such as Tenoretic (atenolol, chlorthalidone fixed-dose combination), Tenormin (atenolol), Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination), Inderal (propranolol) and Zestril (lisinopril). Atnahs Pharma is a UK based company that develop diuretic drugs. Major players in the diuretic market are Merck & Co., Meda Manufacturing GmbH, Pfizer Inc., Glaxosmithkline, Roche, Aton Pharma Inc., Boehringer Ingelheim GmbH, Novartis AG and Teva Pharmaceuticals Industries Ltd. North America is the largest region in the diuretic market in 2021. The Middle East is expected to be the fastest growing region in the global diuretics market during the forecast period. The regions covered in the global diuretic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diuretic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global diuretics market is segmented - 1) By Type: Osmotic Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Thiazides and Thiazide-Like Diuretics, Aldosterone Antagonists 2) By Application: Hypertension, Glaucoma, Heart Failure, Kidney Stones 3) By Distribution: Hospital Pharmacies, Independent Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies 4) By Route of Administration: Intravenous, Oral

The urinary stone treatment devices (or) equipment market consists of sales of urinary stone treatment devices and related services which are used in the treatment and management of stones formed in the kidneys and urinary tract. Stones are made of minerals in the urine that form crystals and grow into stones. About 85% of the stones are made of calcium, and the remaining portion is composed of various substances including cysteine, uric acid, or struvite. The main products in the urinary stone treatment devices/ equipment are the extracorporeal shock wave lithotripsy devices, holmium laser devices, intracorporeal lithotripsy devices, stone retrieval devices, and ureteral stents. Holmium laser devices use pulsed laser and emit light at 2100 nm to break stones in the urinary tract. The stone types involved are calcium stones, struvite, uric acid, cystine, and drug-induced. The various end-users are hospitals, ambulatory surgery centers, and others. The global urinary stone treatment devices and equipment market size is expected to grow from $2.55 billion in 2021 to $2.79 billion in 2022 at a compound annual growth rate (CAGR) of 9.5%. The global urinary stone treatment devices market size is then expected to grow to $3.8 billion in 2026 at a CAGR of 8.0%. The increasing prevalence of Kidney Stones, especially in the geriatric population is driving the urinary stone treatment devices and equipment market growth. The incidence of urolithiasis is reported to be increasing across the globe. According to a study, about 30% of people around the world are obese and nearly 900 million people are geriatrics which is expected to increase to 1.4 billion by 2030. The incidence of kidney stones is globally increasing with an estimated prevalence ranging up to 15%. According to a Robotic Stone survey, the probability of stone formation in Saudi Arabia is 20.1% and 13% in the USA. Stone diseases or urolithiasis are frequent in the aging population. Asia Pacific is presently home to more than half of the world’s aging population above 60 years and the number is expected to rise to 2.45 billion by 2050. Lack of public awareness and proper knowledge about the problems associated with urinary stone diseases, particularly in under-developed countries acts as a major factor hindering market growth. This lack of proper knowledge becomes a roadblock for the Urinary stone treatment device manufacturers because of many cases being unnoticed/unaddressed which amounts to a decrease in demand for these devices. For instance, according to a study conducted in Saudi Arabia, 44% of the participants had a family member suffering from urinary stone disease and 9.6% had urinary stones themselves, which suggests a high prevalence of the ailment in the country. But there was an incidence of lack of awareness and misconceptions among the people in most parts of that region. Companies in the industry are investing in advanced laser technology and robot-assisted surgeries to treat urolithiasis. Urolithiasis is a disease condition where calculi or stones are formed in the kidney, bladder, and urinary tract of the human body. Urolithiasis open surgeries are increasingly conducted with the help of minimally invasive procedures, advanced lasers, enhanced surgical tools, and robot-assisted devices to reduce hospitalization time, be less invasive and enable a shorter bladder catheterization time. For instance, Boston Scientific Co. is investing by way of an agreement with Lumenis, a company offering minimally-invasive clinical solutions, and holmium laser technology, to use and leverage the benefits of advanced laser technology. In March 2019, regarding a field corrective action sent by Medicines and Healthcare products Regulatory Agency (MRHA), a regulatory body for medical devices of the UK, C.R Bard, a subsidiary of Becton, Dickinson, and Company (BD) removed its Women’s Pelvic Organ Prolapse and Stress Urinary Incontinence Mesh devices from the European market. This initiative of ceasing production and distribution of these devices and removal of these products from hospitals and distribution centers was done to protect patient and user safety from these devices. Major players in the urinary stone treatment devices or equipment market are Boston Scientific, Cook Medical, C.R. Bard, DirexGroup, Dornier MedTech, Bard Medical Division, Richard Wolf, Siemens Healthineers AG, Olympus Corporation, and Karl Storz. The regions covered in the global urinary stone treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the global urinary stone treatment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global urinary stone treatment devices and equipment market is segmented - 1) By Product: Extracorporeal Shock Wave Lithotripsy Devices, Holmium Laser Devices, Intracorporeal Lithotripsy Devices, Stone Retrieval Devices, Ureteral Stents 2) By Stone Type: Calcium Stones, Struvite, Uric Acid, Cystine, Drug-Induced 3) By End-User: Hospitals, Ambulatory Surgery Centers, Others

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

Nephrology is a specialty of internal medicine that focuses on the treatment of diseases that affect the kidneys. A nephrologist specializes in treating diseases of the kidney. The market for nephrologists is the revenue generated by the nephrologist by the treating patients with kidney disorders. The global market is calculated by the total volume of nephrologists and the average income (full-time salaries) of a nephrologist. In general, for employed physicians, the compensation includes salary, bonus, and profit-sharing contributions, and for service partners its includes earnings after taxes, and deductable business expenses before income taxes. The revenue of servies partners however includes many elements, including consultation fee, equipment, logistics, procedures performed, practice management, practice setting, risk management, management of other medical personnel in the clinic (Physician assistane and Nurse Practitioners), among others. The appropriate number of nephrologists in a country depends on many factors, including need, priority, and resources, and as such there is no global standard with respect to nephrologist density.